FAK goes nuclear to control antitumor immunity—a new target in cancer immuno-therapy

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

(2015) Alan Serrels et al.   CELL

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

(2014) Y. Zhu et al.   CANCER RESEARCH

Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship

(2014) I. M. Shapiro et al.   Science Translational Medicine

Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy

(2013) Paula D. Bos et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nuclear FAK: a new mode of gene regulation from cellular adhesions

(2013) Ssang-Taek Steve Lim   MOLECULES AND CELLS

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271

(2008) W. G. Roberts et al.   CANCER RESEARCH